nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP3A4—prostate cancer	0.109	1	CbGaD
Vemurafenib—ORM1—Abiraterone—prostate cancer	0.0602	0.105	CbGbCtD
Vemurafenib—ABCC1—Abiraterone—prostate cancer	0.0549	0.0954	CbGbCtD
Vemurafenib—ABCG2—Cabazitaxel—prostate cancer	0.0272	0.0472	CbGbCtD
Vemurafenib—ABCG2—Estrone—prostate cancer	0.0266	0.0462	CbGbCtD
Vemurafenib—ABCC1—Conjugated Estrogens—prostate cancer	0.026	0.0451	CbGbCtD
Vemurafenib—ALB—Abiraterone—prostate cancer	0.0253	0.044	CbGbCtD
Vemurafenib—ABCC1—Mitoxantrone—prostate cancer	0.0236	0.041	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—prostate cancer	0.0191	0.0332	CbGbCtD
Vemurafenib—ALB—Estrone—prostate cancer	0.0183	0.0318	CbGbCtD
Vemurafenib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0182	0.0317	CbGbCtD
Vemurafenib—ABCG2—Conjugated Estrogens—prostate cancer	0.0174	0.0302	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—prostate cancer	0.0158	0.0275	CbGbCtD
Vemurafenib—ABCG2—Estradiol—prostate cancer	0.0153	0.0265	CbGbCtD
Vemurafenib—CYP1A2—Flutamide—prostate cancer	0.0152	0.0263	CbGbCtD
Vemurafenib—CYP2D6—Bicalutamide—prostate cancer	0.0151	0.0262	CbGbCtD
Vemurafenib—ABCC1—Etoposide—prostate cancer	0.0149	0.0259	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—prostate cancer	0.0136	0.0237	CbGbCtD
Vemurafenib—CYP2D6—Abiraterone—prostate cancer	0.0125	0.0217	CbGbCtD
Vemurafenib—CYP1A2—Estrone—prostate cancer	0.011	0.019	CbGbCtD
Vemurafenib—ALB—Estradiol—prostate cancer	0.0105	0.0183	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—prostate cancer	0.0102	0.0176	CbGbCtD
Vemurafenib—ABCG2—Etoposide—prostate cancer	0.00997	0.0173	CbGbCtD
Vemurafenib—CYP3A4—Bicalutamide—prostate cancer	0.00958	0.0166	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—prostate cancer	0.00912	0.0158	CbGbCtD
Vemurafenib—ALB—Prednisone—prostate cancer	0.00905	0.0157	CbGbCtD
Vemurafenib—CYP3A4—Estramustine—prostate cancer	0.00891	0.0155	CbGbCtD
Vemurafenib—CYP3A4—Flutamide—prostate cancer	0.00794	0.0138	CbGbCtD
Vemurafenib—CYP3A4—Abiraterone—prostate cancer	0.00794	0.0138	CbGbCtD
Vemurafenib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00717	0.0125	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—prostate cancer	0.0068	0.0118	CbGbCtD
Vemurafenib—CYP1A2—Estradiol—prostate cancer	0.00629	0.0109	CbGbCtD
Vemurafenib—CYP3A4—Cabazitaxel—prostate cancer	0.00587	0.0102	CbGbCtD
Vemurafenib—CYP3A4—Estrone—prostate cancer	0.00574	0.00997	CbGbCtD
Vemurafenib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00512	0.00889	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—prostate cancer	0.00411	0.00714	CbGbCtD
Vemurafenib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00376	0.00653	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—prostate cancer	0.00341	0.00593	CbGbCtD
Vemurafenib—CYP3A4—Estradiol—prostate cancer	0.0033	0.00573	CbGbCtD
Vemurafenib—BRAF—prostate gland—prostate cancer	0.00311	0.0881	CbGeAlD
Vemurafenib—CYP3A4—Prednisone—prostate cancer	0.00284	0.00493	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—prostate cancer	0.00231	0.00401	CbGbCtD
Vemurafenib—CYP1A2—urine—prostate cancer	0.00229	0.0651	CbGeAlD
Vemurafenib—CYP3A4—Etoposide—prostate cancer	0.00215	0.00374	CbGbCtD
Vemurafenib—RAF1—prostate gland—prostate cancer	0.00207	0.0587	CbGeAlD
Vemurafenib—CYP3A4—Docetaxel—prostate cancer	0.00197	0.00342	CbGbCtD
Vemurafenib—RAF1—seminal vesicle—prostate cancer	0.00175	0.0496	CbGeAlD
Vemurafenib—CYP3A4—urine—prostate cancer	0.00166	0.0471	CbGeAlD
Vemurafenib—CYP2D6—urine—prostate cancer	0.00163	0.0464	CbGeAlD
Vemurafenib—BRAF—bone marrow—prostate cancer	0.0016	0.0454	CbGeAlD
Vemurafenib—RAF1—epithelium—prostate cancer	0.00152	0.0431	CbGeAlD
Vemurafenib—CYP3A4—Doxorubicin—prostate cancer	0.00147	0.00255	CbGbCtD
Vemurafenib—ORM1—prostate gland—prostate cancer	0.00143	0.0405	CbGeAlD
Vemurafenib—RAF1—renal system—prostate cancer	0.00141	0.04	CbGeAlD
Vemurafenib—RAF1—urethra—prostate cancer	0.00139	0.0393	CbGeAlD
Vemurafenib—BRAF—testis—prostate cancer	0.00137	0.0388	CbGeAlD
Vemurafenib—RAF1—bone marrow—prostate cancer	0.00107	0.0302	CbGeAlD
Vemurafenib—ABCC1—prostate gland—prostate cancer	0.00103	0.0293	CbGeAlD
Vemurafenib—BRAF—lymph node—prostate cancer	0.000992	0.0281	CbGeAlD
Vemurafenib—RAF1—testis—prostate cancer	0.000912	0.0259	CbGeAlD
Vemurafenib—ABCC1—seminal vesicle—prostate cancer	0.000875	0.0248	CbGeAlD
Vemurafenib—ABCG2—prostate gland—prostate cancer	0.000856	0.0243	CbGeAlD
Vemurafenib—Etoricoxib—CYP2E1—prostate cancer	0.000832	0.309	CrCbGaD
Vemurafenib—Etoricoxib—CYP2C19—prostate cancer	0.000824	0.306	CrCbGaD
Vemurafenib—ORM1—bone marrow—prostate cancer	0.000736	0.0209	CbGeAlD
Vemurafenib—ABCG2—seminal vesicle—prostate cancer	0.000724	0.0205	CbGeAlD
Vemurafenib—ABCC1—urethra—prostate cancer	0.000692	0.0196	CbGeAlD
Vemurafenib—RAF1—lymph node—prostate cancer	0.000661	0.0187	CbGeAlD
Vemurafenib—ABCG2—urethra—prostate cancer	0.000573	0.0163	CbGeAlD
Vemurafenib—CYP1A2—renal system—prostate cancer	0.000561	0.0159	CbGeAlD
Vemurafenib—ALB—testis—prostate cancer	0.000552	0.0156	CbGeAlD
Vemurafenib—Etoricoxib—CYP3A4—prostate cancer	0.000524	0.195	CrCbGaD
Vemurafenib—Etoricoxib—PTGS2—prostate cancer	0.000513	0.19	CrCbGaD
Vemurafenib—ORM1—lymph node—prostate cancer	0.000456	0.0129	CbGeAlD
Vemurafenib—ABCC1—testis—prostate cancer	0.000455	0.0129	CbGeAlD
Vemurafenib—ABCG2—bone marrow—prostate cancer	0.000441	0.0125	CbGeAlD
Vemurafenib—CYP3A4—renal system—prostate cancer	0.000406	0.0115	CbGeAlD
Vemurafenib—ALB—lymph node—prostate cancer	0.0004	0.0113	CbGeAlD
Vemurafenib—CYP2D6—renal system—prostate cancer	0.0004	0.0113	CbGeAlD
Vemurafenib—ABCG2—testis—prostate cancer	0.000377	0.0107	CbGeAlD
Vemurafenib—ABCC1—lymph node—prostate cancer	0.00033	0.00936	CbGeAlD
Vemurafenib—ABCG2—lymph node—prostate cancer	0.000273	0.00775	CbGeAlD
Vemurafenib—CYP2D6—testis—prostate cancer	0.000258	0.00733	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	9.49e-05	0.000682	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—prostate cancer	9.47e-05	0.00068	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—prostate cancer	9.41e-05	0.000676	CcSEcCtD
Vemurafenib—Dizziness—Goserelin—prostate cancer	9.33e-05	0.00067	CcSEcCtD
Vemurafenib—Erythema multiforme—Capecitabine—prostate cancer	9.28e-05	0.000666	CcSEcCtD
Vemurafenib—Cough—Etoposide—prostate cancer	9.26e-05	0.000665	CcSEcCtD
Vemurafenib—Dizziness—Conjugated Estrogens—prostate cancer	9.24e-05	0.000664	CcSEcCtD
Vemurafenib—Angiopathy—Docetaxel—prostate cancer	9.2e-05	0.000661	CcSEcCtD
Vemurafenib—Eye disorder—Capecitabine—prostate cancer	9.17e-05	0.000659	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—prostate cancer	9.14e-05	0.000657	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—prostate cancer	9.14e-05	0.000656	CcSEcCtD
Vemurafenib—Cardiac disorder—Capecitabine—prostate cancer	9.11e-05	0.000654	CcSEcCtD
Vemurafenib—Chills—Docetaxel—prostate cancer	9.09e-05	0.000653	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—prostate cancer	9.06e-05	0.000651	CcSEcCtD
Vemurafenib—Decreased appetite—Mitoxantrone—prostate cancer	9.06e-05	0.00065	CcSEcCtD
Vemurafenib—Fatigue—Mitoxantrone—prostate cancer	8.98e-05	0.000645	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	8.98e-05	0.000645	CcSEcCtD
Vemurafenib—Vomiting—Goserelin—prostate cancer	8.97e-05	0.000644	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—prostate cancer	8.96e-05	0.000643	CcSEcCtD
Vemurafenib—Constipation—Mitoxantrone—prostate cancer	8.91e-05	0.00064	CcSEcCtD
Vemurafenib—Angiopathy—Capecitabine—prostate cancer	8.9e-05	0.00064	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—prostate cancer	8.9e-05	0.000639	CcSEcCtD
Vemurafenib—Rash—Goserelin—prostate cancer	8.89e-05	0.000639	CcSEcCtD
Vemurafenib—Dermatitis—Goserelin—prostate cancer	8.88e-05	0.000638	CcSEcCtD
Vemurafenib—Vomiting—Conjugated Estrogens—prostate cancer	8.88e-05	0.000638	CcSEcCtD
Vemurafenib—Mediastinal disorder—Capecitabine—prostate cancer	8.84e-05	0.000635	CcSEcCtD
Vemurafenib—Body temperature increased—Estradiol—prostate cancer	8.84e-05	0.000635	CcSEcCtD
Vemurafenib—Headache—Goserelin—prostate cancer	8.84e-05	0.000635	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—prostate cancer	8.82e-05	0.000634	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—prostate cancer	8.82e-05	0.000634	CcSEcCtD
Vemurafenib—Rash—Conjugated Estrogens—prostate cancer	8.81e-05	0.000633	CcSEcCtD
Vemurafenib—Chills—Capecitabine—prostate cancer	8.81e-05	0.000632	CcSEcCtD
Vemurafenib—Dermatitis—Conjugated Estrogens—prostate cancer	8.8e-05	0.000632	CcSEcCtD
Vemurafenib—Headache—Conjugated Estrogens—prostate cancer	8.75e-05	0.000629	CcSEcCtD
Vemurafenib—Alopecia—Capecitabine—prostate cancer	8.67e-05	0.000623	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—prostate cancer	8.67e-05	0.000622	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—prostate cancer	8.64e-05	0.000621	CcSEcCtD
Vemurafenib—Infection—Etoposide—prostate cancer	8.61e-05	0.000618	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—prostate cancer	8.59e-05	0.000617	CcSEcCtD
Vemurafenib—Erythema—Capecitabine—prostate cancer	8.54e-05	0.000614	CcSEcCtD
Vemurafenib—Malnutrition—Capecitabine—prostate cancer	8.54e-05	0.000614	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—prostate cancer	8.53e-05	0.000613	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—prostate cancer	8.46e-05	0.000607	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—prostate cancer	8.42e-05	0.000605	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—prostate cancer	8.38e-05	0.000602	CcSEcCtD
Vemurafenib—Nausea—Goserelin—prostate cancer	8.38e-05	0.000602	CcSEcCtD
Vemurafenib—Dysgeusia—Capecitabine—prostate cancer	8.37e-05	0.000601	CcSEcCtD
Vemurafenib—Nausea—Conjugated Estrogens—prostate cancer	8.3e-05	0.000596	CcSEcCtD
Vemurafenib—Back pain—Capecitabine—prostate cancer	8.26e-05	0.000594	CcSEcCtD
Vemurafenib—Hypersensitivity—Estradiol—prostate cancer	8.24e-05	0.000592	CcSEcCtD
Vemurafenib—Body temperature increased—Mitoxantrone—prostate cancer	8.24e-05	0.000592	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	8.23e-05	0.000591	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—prostate cancer	8.17e-05	0.000587	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—prostate cancer	8.1e-05	0.000582	CcSEcCtD
Vemurafenib—Asthenia—Estradiol—prostate cancer	8.02e-05	0.000576	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—prostate cancer	7.93e-05	0.00057	CcSEcCtD
Vemurafenib—Pruritus—Estradiol—prostate cancer	7.91e-05	0.000568	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—prostate cancer	7.82e-05	0.000562	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—prostate cancer	7.8e-05	0.00056	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—prostate cancer	7.73e-05	0.000555	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—prostate cancer	7.72e-05	0.000555	CcSEcCtD
Vemurafenib—Cough—Docetaxel—prostate cancer	7.7e-05	0.000553	CcSEcCtD
Vemurafenib—Hypersensitivity—Mitoxantrone—prostate cancer	7.68e-05	0.000551	CcSEcCtD
Vemurafenib—Diarrhoea—Estradiol—prostate cancer	7.65e-05	0.000549	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—prostate cancer	7.62e-05	0.000547	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—prostate cancer	7.62e-05	0.000547	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—prostate cancer	7.61e-05	0.000547	CcSEcCtD
Vemurafenib—Erythema—Prednisone—prostate cancer	7.61e-05	0.000547	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—prostate cancer	7.55e-05	0.000542	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—prostate cancer	7.53e-05	0.000541	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—prostate cancer	7.51e-05	0.00054	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—prostate cancer	7.51e-05	0.00054	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—prostate cancer	7.48e-05	0.000537	CcSEcCtD
Vemurafenib—Asthenia—Mitoxantrone—prostate cancer	7.47e-05	0.000537	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—prostate cancer	7.47e-05	0.000537	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—prostate cancer	7.47e-05	0.000536	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	7.46e-05	0.000536	CcSEcCtD
Vemurafenib—Cough—Capecitabine—prostate cancer	7.45e-05	0.000535	CcSEcCtD
Vemurafenib—Constipation—Etoposide—prostate cancer	7.41e-05	0.000532	CcSEcCtD
Vemurafenib—Dizziness—Estradiol—prostate cancer	7.39e-05	0.000531	CcSEcCtD
Vemurafenib—Myalgia—Capecitabine—prostate cancer	7.27e-05	0.000522	CcSEcCtD
Vemurafenib—Arthralgia—Capecitabine—prostate cancer	7.27e-05	0.000522	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.22e-05	0.000519	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—prostate cancer	7.21e-05	0.000518	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—prostate cancer	7.2e-05	0.000517	CcSEcCtD
Vemurafenib—Infection—Docetaxel—prostate cancer	7.15e-05	0.000514	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—prostate cancer	7.15e-05	0.000514	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—prostate cancer	7.13e-05	0.000512	CcSEcCtD
Vemurafenib—Vomiting—Estradiol—prostate cancer	7.11e-05	0.000511	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—prostate cancer	7.06e-05	0.000507	CcSEcCtD
Vemurafenib—Rash—Estradiol—prostate cancer	7.05e-05	0.000506	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—prostate cancer	7.05e-05	0.000506	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—prostate cancer	7.05e-05	0.000506	CcSEcCtD
Vemurafenib—Dermatitis—Estradiol—prostate cancer	7.04e-05	0.000506	CcSEcCtD
Vemurafenib—Headache—Estradiol—prostate cancer	7e-05	0.000503	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—prostate cancer	6.99e-05	0.000502	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	6.99e-05	0.000502	CcSEcCtD
Vemurafenib—Infection—Capecitabine—prostate cancer	6.93e-05	0.000498	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—prostate cancer	6.91e-05	0.000496	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—prostate cancer	6.85e-05	0.000492	CcSEcCtD
Vemurafenib—Nervous system disorder—Capecitabine—prostate cancer	6.84e-05	0.000491	CcSEcCtD
Vemurafenib—Skin disorder—Capecitabine—prostate cancer	6.77e-05	0.000486	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—prostate cancer	6.73e-05	0.000484	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—prostate cancer	6.73e-05	0.000483	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—prostate cancer	6.72e-05	0.000483	CcSEcCtD
Vemurafenib—Nausea—Estradiol—prostate cancer	6.64e-05	0.000477	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—prostate cancer	6.62e-05	0.000476	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—prostate cancer	6.57e-05	0.000472	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—prostate cancer	6.56e-05	0.000471	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.56e-05	0.000471	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—prostate cancer	6.53e-05	0.000469	CcSEcCtD
Vemurafenib—Hypotension—Capecitabine—prostate cancer	6.51e-05	0.000468	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—prostate cancer	6.48e-05	0.000465	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—prostate cancer	6.48e-05	0.000465	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—prostate cancer	6.46e-05	0.000464	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.43e-05	0.000462	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—prostate cancer	6.39e-05	0.000459	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—prostate cancer	6.38e-05	0.000459	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.35e-05	0.000456	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—prostate cancer	6.35e-05	0.000456	CcSEcCtD
Vemurafenib—Decreased appetite—Docetaxel—prostate cancer	6.26e-05	0.00045	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—prostate cancer	6.23e-05	0.000448	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—prostate cancer	6.22e-05	0.000447	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—prostate cancer	6.22e-05	0.000447	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—prostate cancer	6.22e-05	0.000447	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—prostate cancer	6.21e-05	0.000446	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—prostate cancer	6.21e-05	0.000446	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—prostate cancer	6.2e-05	0.000446	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—prostate cancer	6.19e-05	0.000444	CcSEcCtD
Vemurafenib—Infection—Prednisone—prostate cancer	6.17e-05	0.000443	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—prostate cancer	6.16e-05	0.000443	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—prostate cancer	6.16e-05	0.000442	CcSEcCtD
Vemurafenib—Chills—Epirubicin—prostate cancer	6.13e-05	0.000441	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—prostate cancer	6.13e-05	0.00044	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—prostate cancer	6.09e-05	0.000437	CcSEcCtD
Vemurafenib—Decreased appetite—Capecitabine—prostate cancer	6.06e-05	0.000435	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—prostate cancer	6.04e-05	0.000434	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—prostate cancer	6.03e-05	0.000433	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Capecitabine—prostate cancer	6.02e-05	0.000432	CcSEcCtD
Vemurafenib—Fatigue—Capecitabine—prostate cancer	6.01e-05	0.000432	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—prostate cancer	5.98e-05	0.00043	CcSEcCtD
Vemurafenib—Constipation—Capecitabine—prostate cancer	5.96e-05	0.000428	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—prostate cancer	5.95e-05	0.000427	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—prostate cancer	5.95e-05	0.000427	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—prostate cancer	5.93e-05	0.000426	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—prostate cancer	5.91e-05	0.000425	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—prostate cancer	5.87e-05	0.000422	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—prostate cancer	5.83e-05	0.000419	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—prostate cancer	5.76e-05	0.000414	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—prostate cancer	5.74e-05	0.000412	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—prostate cancer	5.73e-05	0.000412	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—prostate cancer	5.7e-05	0.00041	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—prostate cancer	5.69e-05	0.000409	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—prostate cancer	5.68e-05	0.000408	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—prostate cancer	5.66e-05	0.000406	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—prostate cancer	5.59e-05	0.000402	CcSEcCtD
Vemurafenib—Body temperature increased—Capecitabine—prostate cancer	5.51e-05	0.000396	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—prostate cancer	5.51e-05	0.000396	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—prostate cancer	5.51e-05	0.000396	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—prostate cancer	5.51e-05	0.000396	CcSEcCtD
Vemurafenib—Rash—Etoposide—prostate cancer	5.46e-05	0.000392	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—prostate cancer	5.46e-05	0.000392	CcSEcCtD
Vemurafenib—Headache—Etoposide—prostate cancer	5.43e-05	0.00039	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—prostate cancer	5.4e-05	0.000388	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—prostate cancer	5.39e-05	0.000387	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—prostate cancer	5.35e-05	0.000385	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—prostate cancer	5.33e-05	0.000383	CcSEcCtD
Vemurafenib—Constipation—Prednisone—prostate cancer	5.31e-05	0.000381	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—prostate cancer	5.31e-05	0.000381	CcSEcCtD
Vemurafenib—Cough—Epirubicin—prostate cancer	5.19e-05	0.000373	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—prostate cancer	5.17e-05	0.000371	CcSEcCtD
Vemurafenib—Nausea—Etoposide—prostate cancer	5.15e-05	0.00037	CcSEcCtD
Vemurafenib—Hypersensitivity—Capecitabine—prostate cancer	5.14e-05	0.000369	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—prostate cancer	5.09e-05	0.000366	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—prostate cancer	5.07e-05	0.000364	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—prostate cancer	5.07e-05	0.000364	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.03e-05	0.000361	CcSEcCtD
Vemurafenib—Asthenia—Capecitabine—prostate cancer	5e-05	0.000359	CcSEcCtD
Vemurafenib—Pruritus—Capecitabine—prostate cancer	4.93e-05	0.000354	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—prostate cancer	4.93e-05	0.000354	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—prostate cancer	4.91e-05	0.000353	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—prostate cancer	4.86e-05	0.000349	CcSEcCtD
Vemurafenib—Infection—Epirubicin—prostate cancer	4.83e-05	0.000347	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—prostate cancer	4.81e-05	0.000345	CcSEcCtD
Vemurafenib—Diarrhoea—Capecitabine—prostate cancer	4.77e-05	0.000343	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—prostate cancer	4.76e-05	0.000342	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—prostate cancer	4.76e-05	0.000342	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—prostate cancer	4.72e-05	0.000339	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—prostate cancer	4.69e-05	0.000337	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—prostate cancer	4.69e-05	0.000337	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.66e-05	0.000334	CcSEcCtD
Vemurafenib—Dizziness—Capecitabine—prostate cancer	4.61e-05	0.000331	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—prostate cancer	4.58e-05	0.000329	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—prostate cancer	4.58e-05	0.000329	CcSEcCtD
Vemurafenib—Rash—Docetaxel—prostate cancer	4.54e-05	0.000326	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—prostate cancer	4.54e-05	0.000326	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—prostate cancer	4.54e-05	0.000326	CcSEcCtD
Vemurafenib—Headache—Docetaxel—prostate cancer	4.51e-05	0.000324	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—prostate cancer	4.49e-05	0.000323	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—prostate cancer	4.46e-05	0.000321	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—prostate cancer	4.46e-05	0.00032	CcSEcCtD
Vemurafenib—Vomiting—Capecitabine—prostate cancer	4.43e-05	0.000318	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.43e-05	0.000318	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—prostate cancer	4.41e-05	0.000317	CcSEcCtD
Vemurafenib—Rash—Capecitabine—prostate cancer	4.4e-05	0.000316	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—prostate cancer	4.39e-05	0.000316	CcSEcCtD
Vemurafenib—Dermatitis—Capecitabine—prostate cancer	4.39e-05	0.000315	CcSEcCtD
Vemurafenib—Headache—Capecitabine—prostate cancer	4.37e-05	0.000314	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—prostate cancer	4.37e-05	0.000314	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—prostate cancer	4.28e-05	0.000307	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—prostate cancer	4.25e-05	0.000305	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—prostate cancer	4.2e-05	0.000302	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—prostate cancer	4.19e-05	0.000301	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—prostate cancer	4.19e-05	0.000301	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—prostate cancer	4.15e-05	0.000298	CcSEcCtD
Vemurafenib—Nausea—Capecitabine—prostate cancer	4.14e-05	0.000297	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—prostate cancer	4.11e-05	0.000295	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.09e-05	0.000294	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—prostate cancer	3.95e-05	0.000284	CcSEcCtD
Vemurafenib—Rash—Prednisone—prostate cancer	3.92e-05	0.000281	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—prostate cancer	3.91e-05	0.000281	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—prostate cancer	3.91e-05	0.000281	CcSEcCtD
Vemurafenib—Headache—Prednisone—prostate cancer	3.89e-05	0.000279	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.88e-05	0.000279	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—prostate cancer	3.87e-05	0.000278	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—prostate cancer	3.84e-05	0.000276	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—prostate cancer	3.84e-05	0.000276	CcSEcCtD
Vemurafenib—Nausea—Prednisone—prostate cancer	3.69e-05	0.000265	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—prostate cancer	3.58e-05	0.000257	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—prostate cancer	3.55e-05	0.000255	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—prostate cancer	3.48e-05	0.00025	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—prostate cancer	3.44e-05	0.000247	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—prostate cancer	3.32e-05	0.000239	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—prostate cancer	3.31e-05	0.000238	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—prostate cancer	3.22e-05	0.000232	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—prostate cancer	3.21e-05	0.000231	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—prostate cancer	3.18e-05	0.000228	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—prostate cancer	3.09e-05	0.000222	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—prostate cancer	3.08e-05	0.000221	CcSEcCtD
Vemurafenib—Rash—Epirubicin—prostate cancer	3.06e-05	0.00022	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—prostate cancer	3.06e-05	0.00022	CcSEcCtD
Vemurafenib—Headache—Epirubicin—prostate cancer	3.04e-05	0.000219	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—prostate cancer	2.97e-05	0.000213	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—prostate cancer	2.89e-05	0.000207	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—prostate cancer	2.86e-05	0.000205	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—prostate cancer	2.83e-05	0.000204	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—prostate cancer	2.83e-05	0.000203	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—prostate cancer	2.82e-05	0.000202	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—prostate cancer	2.67e-05	0.000192	CcSEcCtD
Vemurafenib—CYP3A4—Metabolism—GSTO1—prostate cancer	2.52e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.52e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAT2—prostate cancer	2.52e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INS—prostate cancer	2.52e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—prostate cancer	2.52e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.52e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—prostate cancer	2.51e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2A6—prostate cancer	2.51e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—prostate cancer	2.5e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.5e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—prostate cancer	2.5e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NQO1—prostate cancer	2.49e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ITPR1—prostate cancer	2.47e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREBBP—prostate cancer	2.47e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TH—prostate cancer	2.45e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—prostate cancer	2.44e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—prostate cancer	2.44e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—prostate cancer	2.44e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKR1C3—prostate cancer	2.44e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—prostate cancer	2.43e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.43e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—prostate cancer	2.43e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.43e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PRKACB—prostate cancer	2.42e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCB2—prostate cancer	2.42e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—prostate cancer	2.42e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LRP2—prostate cancer	2.42e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.42e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—prostate cancer	2.4e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP17A1—prostate cancer	2.4e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—prostate cancer	2.4e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.38e-06	1.73e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—prostate cancer	2.38e-06	1.73e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—P4HB—prostate cancer	2.37e-06	1.72e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.37e-06	1.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—prostate cancer	2.36e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAP2K1—prostate cancer	2.36e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—prostate cancer	2.34e-06	1.7e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—prostate cancer	2.34e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—prostate cancer	2.34e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—prostate cancer	2.32e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—prostate cancer	2.32e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—prostate cancer	2.31e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GGT1—prostate cancer	2.31e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—prostate cancer	2.31e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.31e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—prostate cancer	2.31e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—prostate cancer	2.3e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—prostate cancer	2.29e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOA2—prostate cancer	2.29e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—prostate cancer	2.28e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOA1—prostate cancer	2.27e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—prostate cancer	2.27e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—prostate cancer	2.27e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—prostate cancer	2.25e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.25e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.24e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—prostate cancer	2.24e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—prostate cancer	2.23e-06	1.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—prostate cancer	2.22e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MED12—prostate cancer	2.21e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—prostate cancer	2.21e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNG5—prostate cancer	2.2e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A1—prostate cancer	2.19e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC5A5—prostate cancer	2.18e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—prostate cancer	2.17e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RXRA—prostate cancer	2.16e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—prostate cancer	2.15e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JAK2—prostate cancer	2.15e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2E1—prostate cancer	2.13e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—prostate cancer	2.13e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—prostate cancer	2.12e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA3—prostate cancer	2.11e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—prostate cancer	2.11e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—prostate cancer	2.11e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—prostate cancer	2.11e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—prostate cancer	2.11e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—prostate cancer	2.1e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—prostate cancer	2.1e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—prostate cancer	2.09e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—prostate cancer	2.09e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—prostate cancer	2.09e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—prostate cancer	2.09e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—COMT—prostate cancer	2.08e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TH—prostate cancer	2.08e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—prostate cancer	2.07e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—prostate cancer	2.07e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—prostate cancer	2.07e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—prostate cancer	2.07e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—prostate cancer	2.07e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.06e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP3A4—prostate cancer	2.05e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—prostate cancer	2.05e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.04e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ITPR1—prostate cancer	2.04e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—prostate cancer	2.04e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—prostate cancer	2.04e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—prostate cancer	2.03e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1B1—prostate cancer	2.02e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HPGDS—prostate cancer	2.02e-06	1.46e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C19—prostate cancer	2e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARA—prostate cancer	2e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—prostate cancer	1.99e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—prostate cancer	1.97e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—prostate cancer	1.96e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—prostate cancer	1.96e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.96e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACHE—prostate cancer	1.96e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GGT1—prostate cancer	1.96e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.93e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—prostate cancer	1.93e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—prostate cancer	1.93e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOA1—prostate cancer	1.93e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—prostate cancer	1.92e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—prostate cancer	1.92e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—prostate cancer	1.92e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—prostate cancer	1.91e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—prostate cancer	1.91e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.9e-06	1.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—prostate cancer	1.88e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.88e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—prostate cancer	1.88e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—prostate cancer	1.87e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.87e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—prostate cancer	1.87e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—prostate cancer	1.86e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.85e-06	1.34e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—prostate cancer	1.84e-06	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RXRA—prostate cancer	1.83e-06	1.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—prostate cancer	1.83e-06	1.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—prostate cancer	1.81e-06	1.31e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.81e-06	1.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—prostate cancer	1.8e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.8e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—prostate cancer	1.79e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.78e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—prostate cancer	1.78e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—prostate cancer	1.77e-06	1.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—prostate cancer	1.77e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—COMT—prostate cancer	1.77e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.76e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—prostate cancer	1.76e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—prostate cancer	1.76e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—prostate cancer	1.76e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—prostate cancer	1.75e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—prostate cancer	1.74e-06	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ITPR1—prostate cancer	1.73e-06	1.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—prostate cancer	1.72e-06	1.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—prostate cancer	1.71e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—prostate cancer	1.7e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.7e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—prostate cancer	1.68e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.68e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—prostate cancer	1.68e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARA—prostate cancer	1.65e-06	1.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.64e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—prostate cancer	1.64e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—prostate cancer	1.63e-06	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—prostate cancer	1.63e-06	1.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INS—prostate cancer	1.62e-06	1.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—prostate cancer	1.61e-06	1.17e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—prostate cancer	1.61e-06	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TH—prostate cancer	1.6e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—prostate cancer	1.59e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—prostate cancer	1.59e-06	1.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CREBBP—prostate cancer	1.59e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—prostate cancer	1.59e-06	1.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—prostate cancer	1.58e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—prostate cancer	1.57e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—prostate cancer	1.57e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—prostate cancer	1.56e-06	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.56e-06	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—prostate cancer	1.55e-06	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.53e-06	1.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—prostate cancer	1.52e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GGT1—prostate cancer	1.51e-06	1.1e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—prostate cancer	1.51e-06	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—prostate cancer	1.47e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—prostate cancer	1.47e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—prostate cancer	1.46e-06	1.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—prostate cancer	1.45e-06	1.05e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—prostate cancer	1.43e-06	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—prostate cancer	1.43e-06	1.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—prostate cancer	1.42e-06	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.42e-06	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RXRA—prostate cancer	1.41e-06	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARA—prostate cancer	1.4e-06	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—COMT—prostate cancer	1.36e-06	9.89e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.36e-06	9.84e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—prostate cancer	1.35e-06	9.82e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INS—prostate cancer	1.34e-06	9.72e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.33e-06	9.68e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—prostate cancer	1.32e-06	9.55e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—prostate cancer	1.31e-06	9.53e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CREBBP—prostate cancer	1.31e-06	9.52e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—prostate cancer	1.3e-06	9.44e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—prostate cancer	1.3e-06	9.42e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—prostate cancer	1.26e-06	9.15e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.26e-06	9.12e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.25e-06	9.04e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.24e-06	9.03e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—prostate cancer	1.24e-06	9.03e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—prostate cancer	1.22e-06	8.88e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—prostate cancer	1.2e-06	8.74e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—prostate cancer	1.2e-06	8.73e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.2e-06	8.7e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.18e-06	8.57e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—prostate cancer	1.17e-06	8.52e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.17e-06	8.5e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—prostate cancer	1.14e-06	8.24e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INS—prostate cancer	1.14e-06	8.23e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CREBBP—prostate cancer	1.11e-06	8.07e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—prostate cancer	1.1e-06	7.99e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—prostate cancer	1.1e-06	7.99e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.08e-06	7.87e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—prostate cancer	1.08e-06	7.85e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARA—prostate cancer	1.08e-06	7.84e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—prostate cancer	1.07e-06	7.8e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—prostate cancer	1.06e-06	7.69e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.05e-06	7.65e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—prostate cancer	1.02e-06	7.37e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—prostate cancer	1.02e-06	7.37e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—prostate cancer	9.95e-07	7.22e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—prostate cancer	9.37e-07	6.8e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—prostate cancer	9.25e-07	6.71e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—prostate cancer	9.19e-07	6.67e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—prostate cancer	9.1e-07	6.6e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—prostate cancer	8.94e-07	6.48e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INS—prostate cancer	8.76e-07	6.36e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CREBBP—prostate cancer	8.58e-07	6.22e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.14e-07	5.9e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—prostate cancer	8.01e-07	5.81e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—prostate cancer	7.94e-07	5.76e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—prostate cancer	7.68e-07	5.57e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—prostate cancer	7.57e-07	5.49e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.09e-07	5.14e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—prostate cancer	7.03e-07	5.1e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—prostate cancer	6.61e-07	4.8e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—prostate cancer	6.54e-07	4.75e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—prostate cancer	6.13e-07	4.45e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—prostate cancer	5.84e-07	4.24e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—prostate cancer	5.6e-07	4.06e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—prostate cancer	5.4e-07	3.92e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—prostate cancer	4.58e-07	3.32e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.32e-07	3.14e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—prostate cancer	3.53e-07	2.56e-06	CbGpPWpGaD
